Science & Technology
Combining Host-Directed and Direct-Acting Antivirals to form a Broad-Spectrum MCM
Department of Defense — Office for Chemical and Biological Defense
Opportunity #: W911-SR-25-C-A010
Award Ceiling
$204K
Award Floor
$204K
Close Date
Feb 3, 2026
Total Funding
$204K
Expected Awards
1
Posted Date
Jul 29, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-W911-SR-25-C-A010
Description
SBIR Phase Phase I award: "Combining Host-Directed and Direct-Acting Antivirals to form a Broad-Spectrum MCM" awarded to CFD Research Corporation in Huntsville, Alabama. Funded by Department of Defense (Office for Chemical and Biological Defense). Award amount: $203,982. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.